Intuitive Surgical Set to Announce Q1 2025 Earnings Amid Optimistic Projections

With a market capitalization of $160.8 billion, Intuitive Surgical, Inc. (ISRG) specializes in developing, manufacturing, and marketing da Vinci surgical systems along with the Ion endoluminal system. The company focuses on products that enhance the quality and accessibility of minimally invasive care for physicians and healthcare providers. Based in Sunnyvale, California, Intuitive Surgical is anticipated to release its fiscal Q1 2025 earnings results after the market closes on Tuesday, April 22.

As the earnings announcement approaches, analysts project that ISRG will report adjusted earnings of $1.36 per share. This figure reflects a significant increase of 17.2% compared to $1.16 per share from the same quarter last year. Notably, the company has outperformed Wall Street’s bottom-line estimates for the past four quarters. In Q4 2024, Intuitive Surgical surpassed the consensus EPS estimate by an impressive 36.9%.

For the entirety of fiscal 2025, analysts forecast ISRG’s adjusted EPS to be $6.43, a slight decline from $6.48 reported in fiscal 2024. Nonetheless, adjusted EPS is expected to recover with a year-over-year growth of nearly 18.7%, reaching $7.63 in fiscal 2026.

In the past 52 weeks, ISRG stock has appreciated by 19.2%. This performance stands in stark contrast to the S&P 500 Index’s ($SPX) decline of 1.4% and the Health Care Select Sector SPDR Fund’s (XLV) drop of 4.7% over the same timeframe.

After posting strong Q4 2024 earnings on January 23, Intuitive Surgical’s shares dropped by 4% the following day. The results highlighted a robust quarter, with a 25% year-over-year revenue increase to $2.4 billion, surpassing market expectations. Adjusted EPS stood at $2.21, driven by an 18% rise in Da Vinci procedures along with increased system sales. Despite these positive results, the stock reacted negatively due to the company’s 2025 outlook, which indicated a potential slowdown with estimated procedure growth between 13% and 16%, falling short of both 2024 growth rates and the 16% consensus from Wall Street.

Currently, the consensus rating among analysts for ISRG stock remains moderately positive, reflecting a “Moderate Buy” rating overall. Out of 28 analysts monitoring the stock, there are 18 “Strong Buys,” two “Moderate Buys,” and eight “Holds.” The mean price target is set at $630.92, indicating a potential upside of 39.7% from when this report was compiled.

On the date of publication, Sohini Mondal did not hold (either directly or indirectly) positions in any of the securities mentioned herein. All information and data are intended for informational purposes only. For further details, please view the Barchart Disclosure Policy here.

 

More news from Barchart

The views and opinions expressed herein are those of the author and may not necessarily reflect those of Nasdaq, Inc.